Cidara Therapeutics, Inc. Aktie News

Merck's agreement to acquire Cidara Therapeutics for about $9.2 billion gives hVIVO PLC (AIM:HVO) a moment of reflected glory. Peel Hunt's analysts highlight that Cidara's lead antiviral, CD388, advanced into late-stage development on the back of data generated through hVIVO's human challenge trial platform.

hVIVO PLC (AIM:HVO) has praised its long-running partner Cidara Therapeutics after the American biotech agreed to be bought by MSD in a deal worth about $9.2 billion, saying the takeover highlights the value of its specialist work in early-stage drug development. The London-listed research group, which runs human challenge trials, studies in which volunteers are deliberately exposed to a virus ...

Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) t...

Bought 520,310 additional shares; position value rose by approximately $167.48 million Post-trade stake: 3,020,990 shares valued at $289.29 million CDTX is now the fund's 3rd-largest holding, accounting for approximately 19.2% of AUM

Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium to the biotech's prior trading price, the bid caused its shares to surge.

In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.

California-based TCG Crossover Management sold 1 million shares of Cidara Therapeutics, cutting its stake by approximately $49 million in the third quarter. The transaction value equaled about 2.4% of the fund's 13F assets under management at quarter-end.

Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug.